Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission?

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Outcomes for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in the pre-imatinib era were poor, particularly if patients did not receive an allogeneic hematopoietic stem cell transplant. This led to the recommendation that all patients with Ph+ ALL, if they were transplant candidates, should be transplanted. With the introduction of imatinib and subsequently other tyrosine kinase inhibitors, patient outcomes improved dramatically, raising the question of whether transplant in first complete molecular remission for these patients is really necessary. This review looks at evidence from clinical studies around the world in an attempt to answer this question.

Original languageEnglish (US)
Pages (from-to)345-350
Number of pages6
JournalBest Practice and Research: Clinical Haematology
Volume29
Issue number4
DOIs
StatePublished - Dec 1 2016

Fingerprint

Philadelphia Chromosome
Transplants
Chromosomes
Hematopoietic Stem Cells
Stem cells
Protein-Tyrosine Kinases
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Imatinib Mesylate

Keywords

  • Acute lymphoblastic leukemia
  • ALL
  • Allogeneic
  • Cytogenetics
  • Dasatinib
  • Imatinib
  • Minimal residual disease
  • MRD
  • Nilotinib
  • Ph+
  • Philadelphia chromosome positive
  • Ponatinib
  • Stem cell transplant
  • TKI
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Clinical Biochemistry

Cite this

@article{0930fd5fb0eb4785aa167a82e7b021b1,
title = "Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission?",
abstract = "Outcomes for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in the pre-imatinib era were poor, particularly if patients did not receive an allogeneic hematopoietic stem cell transplant. This led to the recommendation that all patients with Ph+ ALL, if they were transplant candidates, should be transplanted. With the introduction of imatinib and subsequently other tyrosine kinase inhibitors, patient outcomes improved dramatically, raising the question of whether transplant in first complete molecular remission for these patients is really necessary. This review looks at evidence from clinical studies around the world in an attempt to answer this question.",
keywords = "Acute lymphoblastic leukemia, ALL, Allogeneic, Cytogenetics, Dasatinib, Imatinib, Minimal residual disease, MRD, Nilotinib, Ph+, Philadelphia chromosome positive, Ponatinib, Stem cell transplant, TKI, Tyrosine kinase inhibitor",
author = "Litzow, {Mark R}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.beha.2016.10.009",
language = "English (US)",
volume = "29",
pages = "345--350",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "4",

}

TY - JOUR

T1 - Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission?

AU - Litzow, Mark R

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Outcomes for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in the pre-imatinib era were poor, particularly if patients did not receive an allogeneic hematopoietic stem cell transplant. This led to the recommendation that all patients with Ph+ ALL, if they were transplant candidates, should be transplanted. With the introduction of imatinib and subsequently other tyrosine kinase inhibitors, patient outcomes improved dramatically, raising the question of whether transplant in first complete molecular remission for these patients is really necessary. This review looks at evidence from clinical studies around the world in an attempt to answer this question.

AB - Outcomes for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in the pre-imatinib era were poor, particularly if patients did not receive an allogeneic hematopoietic stem cell transplant. This led to the recommendation that all patients with Ph+ ALL, if they were transplant candidates, should be transplanted. With the introduction of imatinib and subsequently other tyrosine kinase inhibitors, patient outcomes improved dramatically, raising the question of whether transplant in first complete molecular remission for these patients is really necessary. This review looks at evidence from clinical studies around the world in an attempt to answer this question.

KW - Acute lymphoblastic leukemia

KW - ALL

KW - Allogeneic

KW - Cytogenetics

KW - Dasatinib

KW - Imatinib

KW - Minimal residual disease

KW - MRD

KW - Nilotinib

KW - Ph+

KW - Philadelphia chromosome positive

KW - Ponatinib

KW - Stem cell transplant

KW - TKI

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84997771395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997771395&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2016.10.009

DO - 10.1016/j.beha.2016.10.009

M3 - Review article

C2 - 27890258

AN - SCOPUS:84997771395

VL - 29

SP - 345

EP - 350

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 4

ER -